Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cara Therapeutics (CARA)

Cara Therapeutics (CARA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 949,064
  • Shares Outstanding, K 40,028
  • Annual Sales, $ 13,470 K
  • Annual Income, $ -74,010 K
  • 60-Month Beta 2.31
  • Price/Sales 69.24
  • Price/Cash Flow N/A
  • Price/Book 9.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.59
  • Number of Estimates 6
  • High Estimate -0.49
  • Low Estimate -0.72
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -15.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.12 +7.35%
on 09/10/19
24.73 -3.99%
on 08/22/19
+0.40 (+1.69%)
since 08/16/19
3-Month
19.52 +21.64%
on 06/25/19
27.55 -13.81%
on 07/17/19
+3.91 (+19.68%)
since 06/17/19
52-Week
12.19 +94.79%
on 12/24/18
27.55 -13.81%
on 07/17/19
+2.55 (+12.00%)
since 09/17/18

Most Recent Stories

More News
Stocks Slide to Start September

Stocks Slide to Start September

UAL : 90.00 (+1.40%)
SKX : 35.27 (-2.27%)
PPC : 31.23 (+1.04%)
NRG : 39.03 (-0.05%)
ZUMZ : 31.87 (-2.42%)
FRO : 8.78 (-2.55%)
WWE : 75.92 (+2.43%)
GM : 38.28 (+2.88%)
DBD : 13.57 (+0.89%)
CBRE : 53.91 (-0.39%)
DVA : 61.65 (-2.58%)
SINA : 44.65 (-0.89%)
MTZ : 65.38 (-1.48%)
CARA : 23.73 (+0.08%)
GES : 17.98 (-3.70%)
QCOM : 78.72 (+0.87%)
SSW : 11.35 (-0.87%)
RCII : 26.11 (+1.75%)
ARNC : 27.24 (+0.15%)
GRUB : 64.48 (-2.17%)
PANW : 212.69 (-1.44%)
CRM : 153.42 (+0.27%)
SWK Holdings Corporation Files Application for Uplisting to NASDAQ Capital Market

SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, announced today that the Company has submitted its formal application to list its common shares...

CARA : 23.73 (+0.08%)
Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA(TM)

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, today announced its entry into a definitive licensing...

CARA : 23.73 (+0.08%)
Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence(R) Oral Formulation Technology

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting...

CARA : 23.73 (+0.08%)
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 4.92% and 1.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

CARA : 23.73 (+0.08%)
Cara: 2Q Earnings Snapshot

STAMFORD, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Wednesday reported a loss of $23 million in its second quarter.

CARA : 23.73 (+0.08%)
Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa...

CARA : 23.73 (+0.08%)
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting...

CARA : 23.73 (+0.08%)
Watch for Cara Therapeutic to Potentially Rebound After Falling 11.53% Yesterday

Cara Therapeutic (NASDAQ:CARA) traded in a range yesterday that spanned from a low of $22.91 to a high of $24.04. Yesterday, the shares fell 11.5%, which took the trading range below the 3-day low of...

CARA : 23.73 (+0.08%)
Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock

Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting...

CARA : 23.73 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CARA with:

Business Summary

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

See More

Key Turning Points

2nd Resistance Point 24.26
1st Resistance Point 23.98
Last Price 23.73
1st Support Level 23.28
2nd Support Level 22.86

See More

52-Week High 27.55
Last Price 23.73
Fibonacci 61.8% 21.68
Fibonacci 50% 19.87
Fibonacci 38.2% 18.06
52-Week Low 12.19

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar